PA
NVMI

PharVision Advisers’s Nova NVMI Stock Holding History

PharVision Advisers’s Portfolio NVMI Stock Details NVMI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,703
Closed -$335K – 446
2024
Q4 		$335K Buy
+1,703
New +$327K 0.28% 121

Other funds holding NVMI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

PharVision Advisers's NVMI Position: Q1 2025 in Review

PharVision Advisers sold out of Nova (NVMI) in Q1 2025, closing a stake of 1,703 shares — an estimated $335K sold.

PharVision Advisers first reported a position in NVMI in Q4 2024 and held it in 1 quarter. The position peaked at $335K in Q4 2024. 250 funds tracked by Wall St. Rank hold NVMI as of Q1 2025.

  • PharVision Advisers reported no remaining Nova position as of Q1 2025 after selling out during the quarter.
  • PharVision Advisers sold 1,703 Nova shares in Q1 2025, an estimated $335K.
  • PharVision Advisers first reported a position in Nova in Q4 2024 and held it in 1 quarter.
  • PharVision Advisers's Nova position peaked at $335K in Q4 2024.
  • 250 funds tracked by Wall St. Rank held Nova as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.